News

Teva Pharmaceutical Industries Ltd. has recently announced that its New Drug Application (NDA) for SD-809 (deutetrabenazine) was accepted by the United States Food and Drug Administration (FDA) to treat chorea linked with Huntington’s disease (HD). HD is a fatal and very rare neurodegenerative disorder that results in the progressive damage of brain’s nerve cells; in western countries, it…

A new study recently published in the journal Cell reported the finding of new genetic variants that can accelerate or delay disease onset in patients with Huntington’s disease. The study is entitled “Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease” and…

Researchers from The Rockefeller University, New York, in collaboration with Columbia University, New York, have recently released results from a study in which they identified the molecular changes that results in the loss of neurons in Parkinson’s disease (PD); a discovery that may have significant implications in discovering…

A study recently published in the journal Molecular Cell revealed a new role played by polyglutamine repeats in addition to their link to neurodegenerative disorders. The study is entitled “Variable Glutamine-Rich Repeats Modulate Transcription Factor Activity” and was led by researchers at the Katholieke Universiteit (KU)…

In a recent study published in the journal Scientific Reports, researchers showed that a new test developed by a team of researchers at the UBC allows clinicians to quantity the effects of gene silencing therapy for patients with Huntington’s disease (HD) and will support the first…

A groundbreaking research initiative on cell reprogramming for drug development against Huntington’s disease recently received $1.19 million worth of funding for the next 3 years, thanks to the Health Research Council to University of Auckland. Lead investigator and neuroscientist, Associate Professor Bronwen Connor, will attempt to better understand the disease, particularly…

A multi-institutional team with researchers from the Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium recently published in the journal Cell a new breakthrough in Huntington’s disease by identifying new genetic variants that can accelerate or delay symptom onset in patients. The study is entitled “…

In a new study entitled “Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer” researchers determined the structure of a key receptor underlying neurodegenerative diseases, including Parkinson’s disease, and showed how current drugs targeting these receptors and used to treat Parkinson’s can…

In a new study entitled “Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells” researchers showed that providing low-dose radiation to human pluripotent stem cells can enhance gene-editing, allowing a faster and less expensive throughput of edited cells to understand and find the cure for several diseases…

Isis Pharmaceuticals, Inc. a leading company in RNA-targeted drug discovery and development, recently announced they will initiate a new Phase I/IIa clinical trial of ISIS_HTTRx for the treatment of Huntington’s disease (HD). Roche will give Isis a milestone payment of $22 million for the initiation of the trial. The placebo-controlled,…